HLB Pharmaceutical Co., Ltd (047920.KQ)
KRW 20500.0
(2.5%)
KRW 20500.0
(2.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -19.42 Billion KRW | -64.96% |
| 2022 | -11.77 Billion KRW | 10.96% |
| 2021 | -13.22 Billion KRW | 82.33% |
| 2020 | -74.84 Billion KRW | -15934.08% |
| 2019 | 472.65 Million KRW | 106.7% |
| 2018 | -7.05 Billion KRW | -29.61% |
| 2017 | -5.44 Billion KRW | -1043.34% |
| 2016 | 577.41 Million KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.6 Billion KRW | -131.01% |
| 2024 Q2 | 496.29 Million KRW | 130.85% |
| 2023 Q3 | -7.64 Billion KRW | 56.78% |
| 2023 FY | -19.42 Billion KRW | -64.96% |
| 2023 Q4 | 5.18 Billion KRW | 167.9% |
| 2023 Q2 | -17.68 Billion KRW | -2603.18% |
| 2023 Q1 | 706.33 Million KRW | 133.67% |
| 2022 FY | -11.77 Billion KRW | 10.96% |
| 2022 Q1 | -3.32 Billion KRW | -310.35% |
| 2022 Q4 | -2.09 Billion KRW | 52.23% |
| 2022 Q3 | -4.39 Billion KRW | -123.94% |
| 2022 Q2 | -1.96 Billion KRW | 41.09% |
| 2021 Q3 | -5.99 Billion KRW | 0.0% |
| 2021 FY | -13.22 Billion KRW | 82.33% |
| 2021 Q4 | 1.58 Billion KRW | 126.38% |
| 2020 FY | -74.84 Billion KRW | -15934.08% |
| 2019 FY | 472.65 Million KRW | 106.7% |
| 2018 FY | -7.05 Billion KRW | -29.61% |
| 2017 FY | -5.44 Billion KRW | -1043.34% |
| 2016 FY | 577.41 Million KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| CMG Pharmaceutical Co., Ltd. | 6.45 Billion KRW | 400.951% |
| Celltrion Pharm, Inc. | 21.26 Billion KRW | 191.359% |
| Huons Global Co., Ltd. | 38.38 Billion KRW | 150.614% |
| DongKook Pharmaceutical Co., Ltd. | 47.17 Billion KRW | 141.181% |
| Enzychem Lifesciences Corporation | -9.32 Billion KRW | -108.306% |
| Humedix Co., Ltd. | 24.82 Billion KRW | 178.271% |
| Boditech Med Inc. | 25.94 Billion KRW | 174.875% |
| EuBiologics Co., Ltd. | -13.87 Billion KRW | -39.978% |
| FutureChem Co.,Ltd | -6.7 Billion KRW | -189.575% |
| Huons Co., Ltd. | 50.47 Billion KRW | 138.491% |
| BNC Korea Co., Ltd. | 25.68 Billion KRW | 175.634% |
| AptaBio Therapeutics Inc. | -12.06 Billion KRW | -61.068% |